Low-dose Radiation Therapy and Stereotactic Body Radiation Therapy Combined With PD-1 Inhibitor Sintilimab and Chemotherapy Versus PD-1 Inhibitor Combined With Chemotherapy as First-line Treatment for Patients With Advanced Squamous Cell Lung Cancer: A Randomized, Phase II Multicenter Clinical Trial
Latest Information Update: 07 Sep 2025
At a glance
- Drugs Sintilimab (Primary)
- Indications Squamous cell cancer
- Focus Therapeutic Use
Most Recent Events
- 15 Apr 2024 Planned End Date changed from 1 Feb 2027 to 28 Feb 2027.
- 15 Apr 2024 Planned primary completion date changed from 1 Feb 2027 to 28 Feb 2027.
- 15 Apr 2024 Status changed from not yet recruiting to recruiting.